NCT06917664 Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease
| NCT ID | NCT06917664 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | China National Center for Cardiovascular Diseases |
| Condition | Coronary Artery Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 220 participants |
| Start Date | 2025-06-05 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 220 participants in total. It began in 2025-06-05 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the effect of angiotensin receptor/neprilysin inhibitors (ARNI) on improving ischemic mitral regurgitation (IMR) in patients with coronary artery disease undergoing isolated coronary artery bypass grafting (CABG) through a randomized controlled clincial trial.
Eligibility Criteria
Inclusion Criteria: 1. Fully informed and voluntarily signed informed consent; 2. Received CABG and moderate IMR was diagnosed on two consecutive preoperative transthoracic echocardiography (according to 2021 ESC/EACTS Guidance Standards ) Exclusion Criteria: 1.Symptomatic hypotension and/or a SBP \< 100 mmHg at screening; 2.Estimated GFR \< 30 mL/min/1.73m2; 3.Serum potassium \> 5 mmol/L at screening; 4.History of angioedema or unacceptable side effects while receiving ACE inhibitors or ARBs; 5.Patients receiving mitral valve intervention at the same time, or have participated in other clinical trials, or are unwilling to participate in this study.
Contact & Investigator
Wei Zhao
STUDY CHAIR
China National Center for Cardiovascular Diseases
Frequently Asked Questions
Who can join the NCT06917664 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06917664 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06917664 currently recruiting?
Yes, NCT06917664 is actively recruiting participants. Contact the research team at chenlianx1@163.com for enrollment information.
Where is the NCT06917664 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06917664 clinical trial?
NCT06917664 is sponsored by China National Center for Cardiovascular Diseases. The principal investigator is Wei Zhao at China National Center for Cardiovascular Diseases. The trial plans to enroll 220 participants.